Aim To investigate the relationship between IL-6 concentration and the risk of carotid artery calcification in chronic kidney disease patients with dialysis (CKD-5D). Methods This analytic observational cross-sectional study includes 95 clinically stable patients who underwent regular haemodialysis for at least three months at Rasyida Renal Hospital Medan, Indonesia. Serum IL-6 level was measured using the enzyme-linked immunosorbent assay (ELISA). Carotid artery calcification was determined by measuring Carotid Intima-Media Thickness (CIMT) using Real-Time B-mode ultrasound. Results There were 53 males (55.8%) of the total samples with the mean duration of haemodialysis of 81.28±67.40 months. Ultrasound examination showed that 28 samples (29.5%) had carotid artery calcification. Statistical test significantly showed that patients with IL-6 ≥81.1 pg/mL were more likely to have carotid artery calcification with an increased risk of 12.92 times (95% CI: 5.54-30.12) compared to the group of patients who had IL-6 level <81.1 pg/mL (p <0.001). Conclusion This study proves that a high level of IL-6 can increase the risk of carotid artery calcification in CKD-5D patients.
Guillermo RD, Griselda, Graciela, Fabian A, Miriam O, Martin L, et al. Prevalence of factor related to vascular calcification in patients with chronic kidney disease on dialysis. MedICINA (BAires). 2017;3.
2.
Goodman W, Goldin J, Kuizon B, Yoon C, Gales B, Sider D, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;1478–83.
3.
Chertow G, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke S. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant. 2004;1489–96.
4.
Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;(39):695–701.
5.
Asmus H, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, et al. Two-year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;1653–61.
6.
Barreto D, Barreto F, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. European Uremic Toxin Work Group (EUTox). Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;550–6.
7.
Nkf Kdoqi Guidelines. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. 2003;
8.
Akihiko K, Odamaki M, Takita T, Maruyama Y, Kumagai H, Hishida A. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 2002;1143–52.
9.
Hirokazu H, Qureshi A, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;139–48.
10.
Sarnak M, Coronado B, Greene T, Wang S, Kusek J, Beck G, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002;327–35.
11.
London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;1731–40.
12.
Lau W, Kalantar-Zadeh K, Vaziri N. The gut as a source of inflammation in chronic kidney disease. Nephron. 2015;92–8.
13.
Spittle M, Hoenich N, Handelman G, Adhikarla R, Homel P, Levin N. Oxidative stress and inflammation in hemodialysis patients. Am kidney dis. 2001;1408–13.
14.
Yudkin J, Kumari M, Ali M, V. Inflammation, obesity, stress, and coronary heart disease: is interleukin-6 the link. Atherosclerosis. 2000;(2):209–14.
15.
Beberashvili I, Sinuani I, Azar A, Yasur H, Shapiro G, Feldman L, et al. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;2253–63.
16.
Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szumilak D, et al. Factors involved in vascular calcification and atherosclerosis in maintenance hemodialysis patients. Nephrol Dial Transplant. 2007;515–21.
Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003;303–9.
19.
Pecoits-Filho R, Lindholm B, Axelsson J. Stenvinkel P. Update on Interleukin -6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003;1042–5.
20.
Benz K, Hilgers K, Daniel C, Amann K. Vascular calcification in chronic kidney disease: the role of inflammation. Intl J Nephrol. 2018;4310379.
21.
Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004;(Suppl 5):59–66.
22.
Wilson P, Kauppila L, Donnell O, Kiel C, Hannan D, Polak M, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation. 2001;1529–34.
23.
Blacher J, Guerin A, Pannier B, Marchais S. London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;938–42.
24.
London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;1731–40.
25.
Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, et al. The presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007;417–25.
26.
Stenvinkel P, Alvestrand A. Inflammation in endstage renal disease: sources, consequences, and therapy. Semin Dial. 2002;329–37.
27.
Rao M. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am Kidney Dis. 2005;(2):324–33.
28.
Bethesda M. USRDS annual data report: Epidemiology of kidney disease in the United States. 2018;
29.
Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int. 2013;368–71.
30.
Baylis C. Sexual dimorphism in the aging kidney: differences in the nitric oxide system. Nat Reviews Nephrol. 2009;384–96.
31.
Neugarten J, Anjali A, Silbiger S. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;319–29.
32.
Lumlertgul D, Kantachuvesiri S, Apichaiyingyurd S, Treamtrakanpon W, Rattanasompattikul M, Gojaseni P, et al. Impact-CKD investigators. Prevalence of and predictive factor for abdominal aortic calcification in Thai chronic kidney disease patients. Ther Apher Dial. 2017;611–9.
33.
Masaru N, Ura Y, Nagata M, Okada Y, Sumida Y, Nishida K, et al. Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with endstage renal disease: a cohort study. BMC Nephrol. 2011;56.
34.
Ok E, Asci G, Toz H, Ok E, Kircelli F, Yilmaz M, et al. Turkish Online Haemodiafiltration Study. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013;192–202.
35.
Longenecker J, Coresh J, Powe N, Levey A, Fink N, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;1918–27.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
